An interventional study of Electroacupuncture in Severe Stroke and Electroacupuncture, sponsored by The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 261st largest by planned enrollment of the 432 interventional ones that give a count, is one of 52 that started in 2021, is one of 264 with no phase, reaches primary completion later than 120 of the 262 other live ones, and was the 250th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Qingdao Central Hospital · Sites in China
Ages 18–75
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 52 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
68 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 68 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of electroacupuncture in assisting ventilator weaning in patients with severe stroke
Disuse atrophy of the major respiratory muscles and diaphragmatic dysfunction often develop during mechanical ventilation, and cause difficulties in ventilator weaning. Electroacupuncture was indicated to promote activities of diaphragm and improve diaphragmatic function. Our aim is to evaluate the efficacy of electroacupuncture in assisting ventilator weaning in patients with severe stroke. 100 eligible patients will be randomly assigned to receive electroacupuncture or sham electroacupuncture treatment one session per day until the success of ventilator weaning (up to 21 days). The primay outcome is the ventilation duration within 21 days after enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the electroacupuncture group received acupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36). After skin disinfection, sterile adhesive pads were placed on these acupoints, and acupuncture needles were inserted through the adhesive pads approximately 50 to 60 mm into the skin. Paired electrodes from the electroacupuncture apparatus were attached to the needle handles of Xuanji (CV21) and Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), bilateral Liangmen (ST21), and bilateral Zusanli (ST36). The electroacupuncture stimulation lasted for 30 minutes with an intermittent wave of 50 Hz and a current intensity of 1 to 5mA (preferably with the skin around the acupoints shivering mildly without pain). Participants received 1 treatment session per day until the success of ventilator weaning (up to 21 days).
Other: Electroacupuncture
Participants in the sham electroacupuncture group received sham electroacupuncture with a pragmatic placebo needle on sham acupoints. The sham Xuanji (CV21) point was 1 cun (≈20 mm) above to Xuanji (CV21), the sham Danzhong (CV27) point was 1 cun(≈20mm) above to Danzhong (CV27), the sham Qihai (CV06) point was 1 cun(≈20mm) above to Qihai (CV06), the sham Guanyuan (CV04) point was 1 cun(≈20mm) above to Guanyuan (CV04), the sham Liangmen (ST21) point was 1 cun(≈20mm) lateral to Liangmen (ST21), and the sham Zusanli (ST36) point was 1 cun(≈20mm) lateral to Zusanli (ST36). Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no skin penetration or electricity output.
Other: Electroacupuncture
Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
ventilation duration
hours
Time frame: within 21 days after enrollment
rate of successful ventilator weaning
percentage
Time frame: within 21 days after enrollment
diaphragm muscle thickness
mm
Time frame: on day 7, day 14 and day 21
diaphragm thickening fraction
percentage
Time frame: on day 7, day 14 and day 21
diaphragm excursion
mm
Time frame: on day 7, day 14 and day 21
rate of death
percentage
Time frame: within 21 days after enrollment
Plan to share: No — The detailed datasets used and/or analyzed during the current study are available upon reasonable request.
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 68 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine